RadioMedix, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2006

Location

Houston TX US

Primary Industry

Biotechnology

About

Based in Texas, US, and founded in 2006 by CEO Ebrahim Delpassand, and Izabela Tworowska, RadioMedix, Inc., a.k.a. RadioMedix is a biotechnology company that develops and manufactures radiopharmaceuticals for the diagnosis and treatment of cancer. In October 2022, RadioMedix, Inc. raised USD 40 million in a Series A funding from new investor Portland Investment Counsel Inc. The company’s product line includes cassettes and consumables like elution medium for ITM 68Ge/68Ga generator, reagent set for manual labeling of n.c.a. 177Lu, complementary reagent set, iQS available consumables, and more; generators like gallium-68 generator 68ge/68ga generator, and 188w/188re generator; precursors like PSMA-11 GMP; and radiolabeling synthesizers like smartmedix radiosynthesizer, iQS-TS, and automated theranostics synthesizer. In addition, RadioMedix offers services, such as drug discovery, pre-clinical, investigational new drug manufacturing, analytical services, and commercial-scale manufacturing. RadioMedix plans to use its proceeds from October 2022 funding to advance the research and development (R&D) of its diagnostic and therapeutic radiopharmaceuticals, particularly its flagship AlphaMedix drug, for the treatment of rare and aggressive cancers.

Current Investors

Tjänstebilen, Fusion Pharma

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Diagnostic Equipment, Pharmaceutical Research & Development

Website

www.radiomedix.com

Verticals

HealthTech, Manufacturing

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.